###begin article-title 0
###xml 35 36 31 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 40 41 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 24 29 <span type="species:ncbi:9606">Human</span>
Characterization of the Human alpha1beta1 Soluble Guanylyl Cyclase Promoter
###end article-title 0
###begin p 1
###xml 13 41 13 41 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Comunidad Aut&#243;noma de Madrid</grant-sponsor>
###xml 48 66 48 66 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">CCG07-UAM/BIO-1595</grant-num>
Supported by Comunidad Autonoma de Madrid Grant CCG07-UAM/BIO-1595.
###end p 1
###begin p 2
###xml 262 279 262 279 <email xmlns:xlink="http://www.w3.org/1999/xlink">a.hobbs@ucl.ac.uk</email>
 Recipient of a Wellcome Trust Senior Research Fellowship. To whom correspondence should be addressed: Dept. of Pharmacology, University Collage London, Medical Sciences Bldg., Gower St., London WC1E 6BT, UK. Tel.: 44-20-7679-7161; Fax: 44-20-7679-7298; E-mail: a.hobbs@ucl.ac.uk. 
###end p 2
###begin p 3
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 3
###begin p 4
 applies to Author Choice Articles
###end p 4
###begin p 5
###xml 600 601 596 597 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 610 611 603 604 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 862 863 851 852 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 872 873 858 859 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1192 1193 1170 1171 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1202 1203 1177 1178 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1622 1623 1589 1590 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1632 1633 1596 1597 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1747 1751 1711 1715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 589 594 <span type="species:ncbi:9606">human</span>
###xml 691 696 <span type="species:ncbi:9606">human</span>
###xml 1607 1612 <span type="species:ncbi:9606">human</span>
Soluble guanylyl cyclase (sGC) is the principal receptor for NO and plays a ubiquitous role in regulating cellular function. This is exemplified in the cardiovascular system where sGC governs smooth muscle tone and growth, vascular permeability, leukocyte flux, and platelet aggregation. As a consequence, aberrant NO-sGC signaling has been linked to diseases including hypertension, atherosclerosis, and stroke. Despite these key (patho)physiological roles, little is known about the expressional regulation of sGC. To address this deficit, we have characterized the promoter activity of human alpha1 and beta1 sGC genes in a cell type relevant to cardiovascular (patho)physiology, primary human aortic smooth muscle cells. Luciferase reporter constructs revealed that the 0.3- and 0.5-kb regions upstream of the transcription start sites were optimal for alpha1 and beta1 sGC promoter activity, respectively. Deletion of consensus sites for c-Myb, GAGA, NFAT, NF-kappaB(p50), and CCAAT-binding factor(s) (CCAAT-BF) revealed that these are the principal transcription factors regulating basal sGC expression. In addition, under pro-inflammatory conditions, the effects of the strongest alpha1 and beta1 sGC repressors were enhanced, and enzyme expression and activity were reduced; in particular, NF-kappaB(p50) is pivotal in regulating enzyme expression under such conditions. NO itself also elicited a cGMP-independent negative feedback effect on sGC promoter activity that is mediated, in part, via CCAAT-BF activity. In sum, these data provide a systematic characterization of the promoter activity of human sGC alpha1 and beta1 subunits and identify key transcription factors that govern subunit expression under basal and pro-inflammatory (i.e. atherogenic) conditions and in the presence of ligand NO.
###end p 5
###begin p 6
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 6
###begin p 7
###xml 31 45 31 45 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Wellcome Trust</grant-sponsor>
###xml 188 201 188 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
This work was supported by the Wellcome Trust. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 7
###begin p 8
The on-line version of this article (available at ) contains supplemental Figs. S1-S5.
###end p 8
###begin p 9
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref3">3</xref>
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn4">3</xref>
###xml 435 436 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
###xml 606 607 606 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 621 622 621 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 648 649 648 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 651 652 651 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 676 677 676 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
Nitric oxide is now well established to play key regulatory roles in numerous, disparate physiological and (patho)physiological processes (1-3). Pivotal to NO-mediated modification of cell function is activation of the hemoprotein soluble guanylyl cyclase (sGC)3 and consequent production of the second messenger cGMP, which in turn activates specific cyclic nucleotide-dependent protein kinases, ion channels, and phosphodiesterases (4). This fundamental role for sGC as the principal intracellular receptor for NO is exemplified in the cardiovascular system, where the enzyme governs smooth muscle tone (5) and growth (6), vascular permeability (7, 8), platelet reactivity (9, 10), and leukocyte extravasation (11, 12).
###end p 9
###begin p 10
###xml 85 87 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 263 265 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 322 325 311 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,2</sub>
###xml 334 337 320 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,2</sub>
###xml 375 377 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 407 408 389 390 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 413 414 392 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 424 425 399 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 430 431 402 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 562 564 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 566 568 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 582 584 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 610 611 578 579 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 620 621 585 586 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 680 681 641 642 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 690 691 648 649 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 574 580 <span type="species:ncbi:9606">humans</span>
Soluble GC functions as an obligate heterodimer composed of alpha and beta subunits (13). Within the last decade, the localization and structure of the genes encoding for sGC subunits have been elucidated in several mammalian species, nonvertebrates, and plants (14). In mammals, two isoforms of each subunit, called alpha1,2 and beta1,2, have been cloned and characterized (15). However, to date only alpha1/beta1 and alpha2/beta1 heterodimers have been identified at the protein level. The chromosomal localization of sGC genes has been determined in rodents (16, 17) and humans (18); in both cases the alpha1 and beta1 subunits are co-localized on the same locus, whereas alpha2 and beta2 lie on separate chromosomes.
###end p 10
###begin p 11
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 324 325 320 321 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 365 367 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 397 398 390 391 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 568 569 546 547 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 387 392 <span type="species:ncbi:9606">human</span>
Previous reports have provided evidence that expressional regulation of the enzyme is a key means of modulating NO-sGC signaling. For instance, different tissues possess distinct levels of mRNA for sGC isoforms (19), intimating tissue-specific expression of individual sGC subunits. Furthermore, splice variants of the alpha1 sGC subunit mRNA have been identified (20). In contrast, the human beta1 subunit is encoded by a single transcript (approximately3.5kb), suggesting the translation of a single protein. Such observations suggest that the expression of the beta1 subunit is somewhat invariant, whereas alterations in the expression of the alpha subunit(s) may be an important physiological control mechanism.
###end p 11
###begin p 12
###xml 264 265 261 262 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 347 349 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 351 353 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 472 473 466 467 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 482 483 473 474 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 596 598 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 672 674 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 676 678 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 776 778 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 793 794 778 779 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 876 878 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 1093 1094 1072 1073 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1152 1154 1131 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 1286 1288 1265 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
###xml 1318 1319 1294 1295 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1434 1436 1410 1412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 1438 1440 1414 1416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 1532 1534 1508 1510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 236 240 <span type="species:ncbi:10116">rats</span>
###xml 402 406 <span type="species:ncbi:10116">rats</span>
###xml 1498 1502 <span type="species:ncbi:10116">rats</span>
Changes in the expression of sGC have also been linked with disease states, intimating that expressional regulation of the enzyme is likely to have (patho)physiological significance. For instance, in aged and spontaneously hypertensive rats, expression of the beta1 subunit is diminished and correlates with elevations in systemic blood pressure (21, 22). Moreover, salt-sensitive hypertension in Dahl rats is associated with decreased and increased expression of the beta1 and beta2 subunits, respectively, suggesting that exchange of beta subunits may be critical to blood pressure regulation (16). In animal models of pulmonary hypertension, sGC expression is reduced (23, 24), and pulmonary artery smooth muscle cells exposed to hypoxia lose their ability to express sGC (25). Reduced beta1 sGC expression also correlates with intimal thickening following balloon injury (26). Exposure of cells and/or tissues to pro-inflammatory cytokines, or NO itself, also induces changes in sGC expression. For example, lipopolysaccharide (LPS), interleukin 1beta, and NO donors cause reduced sGC beta1 mRNA expression in pulmonary artery smooth muscle cells (27), and in atherogenic lesions reduced sGC expression is linked to diminished cGMP-dependent signaling and neointimal proliferation (28). In contrast, augmented beta1 subunit expression has been linked to increased nitrovasodilator potency in animals with endothelial dysfunction (29, 30) and increased vasodilator response in aortic rings from rats after myocardial infarction (31).
###end p 12
###begin p 13
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref32">32</xref>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref33">33</xref>
###xml 559 560 556 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 567 569 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 813 814 806 807 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 823 824 813 814 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1115 1116 1101 1102 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1125 1126 1108 1109 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 309 314 <span type="species:ncbi:9606">human</span>
###xml 549 554 <span type="species:ncbi:9606">human</span>
###xml 802 807 <span type="species:ncbi:9606">human</span>
###xml 854 859 <span type="species:ncbi:9606">human</span>
###xml 1104 1109 <span type="species:ncbi:9606">human</span>
###xml 1140 1145 <span type="species:ncbi:9606">human</span>
These observations intimate that expressional regulation of sGC plays a key role in the cardiovascular system, both in terms of physiological homeostasis and pathogenesis. Despite these reports, however, there is a paucity of information regarding the regulation of sGC promoter activity, particularly in the human vasculature where the enzyme performs such an important physiological function. Previous studies have examined the promoter activity of individual sGC subunits in different species (32, 33), yet only a single study has focused on the human beta1 gene (34). Here, a key role for a CCAAT-binding factor (CCAAT-BF) was revealed, although this analysis was conducted in a neuronal, rather than cardiovascular, cell line. Thus, there is a key requirement to understand the factors regulating human alpha1 and beta1 sGC promoter activity in the human vasculature to more fully appreciate the physiological roles and regulation of the NO receptor and how aberrant expression may underlie cardiovascular pathogenesis. To address this need, herein we investigated the transcriptional regulation of human alpha1 and beta1 sGC genes in human aortic smooth muscle cells (HASMCs).
###end p 13
###begin title 14
MATERIALS AND METHODS
###end title 14
###begin p 15
###xml 0 12 0 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cell Culture</italic>
###xml 360 361 354 355 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 111 117 <span type="species:ncbi:9913">bovine</span>
###xml 147 152 <span type="species:ncbi:9606">human</span>
###xml 198 203 <span type="species:ncbi:9606">human</span>
###xml 256 261 <span type="species:ncbi:9606">human</span>
Cell Culture-HASMCs (PromoCell) were cultured in smooth muscle cell growth medium 2 supplemented with 5% fetal bovine serum, 0.5 ng/ml recombinant human epidermal growth factor, 2 ng/ml recombinant human basic fibroblast growth factor, 5 mg/ml recombinant human insulin, and 0.62 ng/ml phenol red (PromoCell). The cells were maintained at 37 degreesC and 5% CO2, and cells in passages 2-10 were used.
###end p 15
###begin p 16
###xml 0 37 0 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Isolation of Genomic Clones for Human</italic>
###xml 43 44 39 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 43 48 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sub>1</sub> and</italic>
###xml 53 54 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 53 67 46 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sub>1</sub> sGC Subunits</italic>
###xml 123 124 112 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 132 133 118 119 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 358 359 340 341 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 368 369 347 348 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 531 532 501 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8242;</sup>
###xml 558 559 524 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 579 580 542 543 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 32 37 <span type="species:ncbi:9606">Human</span>
###xml 185 193 <span type="species:ncbi:9606">Children</span>
###xml 347 352 <span type="species:ncbi:9606">human</span>
Isolation of Genomic Clones for Human alpha1 and beta1 sGC Subunits-Bacterial artificial chromosome clones containing alpha1 or beta1 sGC subunits were purchased from BacPac Resources (Children's Hospital Oakland Research Institute). Bacterial artificial chromosome DNA was isolated according to the manufacturer's protocol. The full promoters of human alpha1 and beta1 sGC were isolated from the bacterial artificial chromosome clones by PCR using Accuprimetrade mark Taq high fidelity DNA polymerase, using primers based on the 5'-flanking regions of alpha1 (AY034777) and beta1 (AY034778) sGC genes including the first exon. The identity of both promoter regions was verified by direct sequencing.
###end p 16
###begin p 17
###xml 0 44 0 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Construction of Luciferase Deletion Plasmids</italic>
###xml 87 88 83 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 97 98 90 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Construction of Luciferase Deletion Plasmids-Different 5'-flanking regions of the alpha1 and beta1 sGC genes upstream of the transcription start site (+1) and extending to the noncoding part of the first exon (+9) were cloned into NheI-XhoI restriction sites of the pGL3-basic luciferase reporter vector (Promega). Fragments were obtained by PCR as previously described for the full promoter. Insertions in the pGL3 reporter vector expressing firefly luciferase were identified by restriction digest, and the integrity of the constructs was confirmed by direct sequencing. Primer sequences used to generate the full promoter, and deletion constructs are shown in supplemental Fig. S1.
###end p 17
###begin p 18
###xml 0 25 0 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Site-directed Mutagenesis</italic>
###xml 193 196 193 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pfu</italic>
Site-directed Mutagenesis-The A0.3- and B0.5-kb fragments, respectively, were subjected to site-directed mutagenesis by using the QuikChange II site-directed kit (Stratagene) and high fidelity Pfu Turbo DNA polymerase (Stratagene). This kit was also used to repair errors during the construction of luciferase deletion constructs. All of the constructs were verified by direct sequencing.
###end p 18
###begin p 19
###xml 0 23 0 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Transient Transfections</italic>
###xml 420 427 418 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla</italic>
###xml 567 568 565 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 613 635 611 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella typhimurium</italic>
###xml 792 793 779 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 839 840 825 826 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 613 635 <span type="species:ncbi:90371">Salmonella typhimurium</span>
Transient Transfections-3,500 HASMCs/well and 15,000 COS-7 cells/well were seeded in 96-well clear plates 1 day before transfection. The cells were transfected with 50 ng of plasmid DNA/well using FuGENE 6 reagent (Roche Applied Science) with a 3:1 ratio (mul reagent:mug DNA). pGL3 control vector (Promega) was used as a transfection control. In each case, the cells were co-transfected with a pRL-TK vector expressing Renilla luciferase (Promega) at a 10:1 ratio (test vector:pRL-TK vector). Twenty-four hours later, where indicated cells were treated with either (a) "pro-inflammatory mixture" (100 mg/ml LPS (Salmonella typhimurium; Sigma), 200 units/ml IFN-gamma, 400 units/ml interleukin-1beta, and 2000 units/ml tumor necrosis factor-alpha (all Preprotech) in cell culture medium) or (b) the NO donor DETA-NONOate (DETA-NO; 0-200 mum).
###end p 19
###begin p 20
###xml 0 17 0 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Luciferase Assays</italic>
###xml 400 407 400 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla</italic>
Luciferase Assays-Forty-eight hours after transfection, the cells were washed in phosphate-buffered saline and lysed for 30 min at room temperature using the passive lysis buffer (Promega). Luciferase activity was determined using the dual luciferase reporter assay system (Promega) on the Wallac Victor 2 Multilabel Counter (PerkinElmer Life Sciences). Firefly luciferase activity was normalized to Renilla luciferase derived from pRL-TK vector, and the data are expressed as relative luciferase light units.
###end p 20
###begin p 21
###xml 0 44 0 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Electrophoretic Mobility Shift Assays (EMSA)</italic>
###xml 171 172 170 171 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 276 278 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref35">35</xref>
Electrophoretic Mobility Shift Assays (EMSA)-HASMC plated in 6-cm tissue culture dishes were stimulated for 2 h with the pro-inflammatory mixture or DETA-NO (100 or 200 mum), nuclear extracts were prepared, and samples were subjected to EMSA, as we have previously described (35). The primers used to generate the double-stranded probes are shown in supplemental Fig. S2.
###end p 21
###begin p 22
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Western Blot Analysis</italic>
###xml 660 661 651 652 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 754 755 742 743 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1006 1017 <span type="species:ncbi:3704">horseradish</span>
###xml 1040 1044 <span type="species:ncbi:9925">goat</span>
###xml 1050 1056 <span type="species:ncbi:9986">rabbit</span>
Western Blot Analysis-Protein concentrations were determined by BCA protein assay (Pierce, distributed by Perbio Sciences Ltd., Northumberland, UK). Equal concentrations of protein were subjected to 15% SDS-PAGE under reducing conditions. The proteins were transferred to a nitrocellulose membrane (Amersham Biosciences) using the mini Trans-blot electrophoresis transfer cell (Bio-Rad). The membranes were stained with Ponceau S stain to confirm equal transfer and incubated in 5% milk in wash buffer (phosphate-buffered saline, 0.1% Tween 20) overnight at 4 degreesC with gentle shaking. The membranes were then incubated with primary antibody (anti-sGC beta1) or anti-glyceraldehyde-3-phosphate dehydrogenase (Abcam, Coventry, UK) diluted 1:2000 (beta1) or 1:1000 (glyceraldehyde-3-phosphate dehydrogenase) in 5% milk in wash buffer for 3 h at room temperature with constant agitation followed by five washes (5 min/wash). The membranes were then incubated with shaking for 1 h at room temperature with horseradish peroxidase-conjugated goat anti-rabbit IgG (Dako, Cambridgeshire, UK) diluted 1:1000 in 5% milk in wash buffer. The membranes were washed as described above, and the proteins were visualized using enhanced chemiluminescence (Amersham Biosciences). The bands were quantified by densitometry using AlphaImager (Alpha Innotech, San Leandro, CA).
###end p 22
###begin p 23
###xml 0 23 0 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyclic GMP Measurements</italic>
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 374 375 374 375 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 394 395 394 395 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 398 399 398 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 420 421 420 421 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 451 452 451 452 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 538 539 537 538 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
Cyclic GMP Measurements-HASMC (106 cells) were plated in 10-cm dishes and 24 h later exposed to the pro-inflammatory mixture for a further 24 h. At this time, the cells were harvested by trypsinization and centrifuged at 200 x g for 10 min. The cell pellet was resuspended in assay buffer (2.36 mg/100 ml Tris-HCl, 760 mg/100 ml NaCl, 22.2 mg/100 ml KCl, 29.6 mg/100 ml MgSO4, 16.6 mg/100 ml Na2HPO4, 0.01 mg/100 ml CaCl2, pH 7.4) and treated with 1 mm 3-isobutyl-1-methylxanthine (Sigma). The cells were then exposed to either 1 or 10 mum spermine-NONOate (Axxora, Nottingham, UK) for 5 min ("basal" samples did not receive spermine-NONOate), and the reaction was terminated by heating at 90 degreesC for 10 min. The cyclic GMP content was then measured using a commercially available assay (Amersham Biosciences).
###end p 23
###begin p 24
###xml 0 39 0 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bioinformatics and Statistical Analysis</italic>
###xml 97 98 93 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 161 168 157 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ensembl</italic>
###xml 218 219 210 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 681 683 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref36">36</xref>
###xml 746 747 736 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 814 815 804 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 118 123 <span type="species:ncbi:10090">mouse</span>
###xml 125 128 <span type="species:ncbi:10116">rat</span>
###xml 134 139 <span type="species:ncbi:9606">human</span>
Bioinformatics and Statistical Analysis-BLAST was used to identify and retrieve orthologous alpha1 sGC promoters from mouse, rat, and human genomes from project Ensembl at The Wellcome Trust Sanger Institute. The alpha1 sGC upstream sequence was analyzed for the presence of repeat regions and transposable elements, using Repeat Masker version open-3.1.5. Confirmation of Pol II promoter was conducted with Promoter Scan II and Novel Neural Network Promoter Prediction. Identification of CpG islands was performed using CpGProD (CpG Island Promoter Detection) software. In silico analysis for transcription factor-binding sites was performed with MatInspector Suite, release 7.4 (36). The results are expressed as the means +/- S.E. A Student's t test was used to determine differences between data groups, where p < 0.05 was considered significant.
###end p 24
###begin title 25
RESULTS
###end title 25
###begin p 26
###xml 0 25 0 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Characterization of the 5</italic>
###xml 26 51 26 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-Flanking Region of Human</italic>
###xml 57 58 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 57 62 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sub>1</sub> and</italic>
###xml 67 68 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 67 78 60 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sub>1</sub> sGC Genes</italic>
###xml 157 158 146 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 167 168 153 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 286 287 268 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 296 297 275 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 495 496 470 471 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 505 506 477 478 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 558 560 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref37">37</xref>
###xml 747 748 715 716 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 798 799 763 764 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1016 1017 977 978 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1055 1056 1013 1014 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1074 1081 1032 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table 1</xref>
###xml 1172 1173 1126 1127 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1181 1182 1132 1133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 46 51 <span type="species:ncbi:9606">Human</span>
Characterization of the 5'-Flanking Region of Human alpha1 and beta1 sGC Genes-The transcriptional start sites were determined by pair-wise blasting of alpha1 and beta1 sGC 5'-flanking regions with the complete mRNA sequences (NM_000856 and NM_000857, respectively). Scanning both alpha1 and beta1 sGC sequences with the Novel Neural Network Algorithms for Improved Eukaryotic Promoter Site Recognition did not reveal any TATA box in close proximity to the transcription start site of both alpha1 and beta1 sGC promoters. Analysis of promoter core elements (37) showed the presence of consensus Inr (initiator) and DPE (downstream core promoter) elements but not TFIIB recognition (BRE) or the newly discovered motif 10 (MTE) elements in the alpha1 sGC promoter (supplemental Fig. S3). For the beta1 sGC promoter, only DPE elements were found (supplemental Fig. S3). GC and CCAAT-BF boxes were detected in both proximal promoters. Furthermore, using Repeat Masker, we were able to identify three repeats in the alpha1 sGC promoter but only one in the beta1 promoter region (Table 1). Finally, CpGProD software did not reveal the presence of CpG islands in either the alpha1 or beta1 sGC promoters.
###end p 26
###begin p 27
###xml 0 7 0 7 <label xmlns:xlink="http://www.w3.org/1999/xlink">TABLE 1</label>
###xml 7 71 7 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The positions are according to the transcription start site (+1)</bold>
###xml 7 71 7 71 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28"><bold>The positions are according to the transcription start site (+1)</bold></p>
###xml 7 71 7 71 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28"><bold>The positions are according to the transcription start site (+1)</bold></p></caption>
###xml 71 77 71 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Repeat</bold>
###xml 71 77 71 77 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Repeat</bold></th>
###xml 77 92 77 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink">No. of elements</bold>
###xml 77 92 77 92 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>No. of elements</bold></th>
###xml 92 97 92 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Begin</bold>
###xml 92 97 92 97 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Begin</bold></th>
###xml 97 100 97 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink">End</bold>
###xml 97 100 97 100 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>End</bold></th>
###xml 100 106 100 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Length</bold>
###xml 100 106 100 106 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Length</bold></th>
###xml 106 128 106 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Percentage of sequence</bold>
###xml 106 128 106 128 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Percentage of sequence</bold></th>
###xml 71 128 71 128 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="1" rowspan="1" align="center" valign="top"><bold>Repeat</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>No. of elements</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Begin</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>End</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Length</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Percentage of sequence</bold></th></tr>
###xml 71 128 71 128 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Repeat</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>No. of elements</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Begin</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>End</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Length</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Percentage of sequence</bold></th></tr></thead>
###xml 128 128 128 128 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"/>
###xml 128 128 128 128 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 128 128 128 128 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 128 128 128 128 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 128 130 128 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bp</italic>
###xml 128 130 128 130 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"><italic>bp</italic></td>
###xml 130 130 130 130 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 128 130 128 130 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"><italic>bp</italic></td><td colspan="1" rowspan="1" align="center" valign="top"/></tr>
###xml 141 142 137 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 130 189 130 185 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Human &#945;<sub>1</sub> sGC promoter repeats according to RepeatMasker</bold>
###xml 189 190 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 189 190 185 186 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>a</italic></bold>
###xml 189 190 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn1"><bold><italic>a</italic></bold></xref>
###xml 130 190 130 186 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"><bold>Human &#945;<sub>1</sub> sGC promoter repeats according to RepeatMasker</bold><xref ref-type="table-fn" rid="tblfn1"><bold><italic>a</italic></bold></xref></td>
###xml 190 190 186 186 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 190 190 186 186 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 190 190 186 186 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 190 190 186 186 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 190 190 186 186 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 130 190 130 186 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"><bold>Human &#945;<sub>1</sub> sGC promoter repeats according to RepeatMasker</bold><xref ref-type="table-fn" rid="tblfn1"><bold><italic>a</italic></bold></xref></td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr>
###xml 190 207 186 203 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;LTR (MaLRs) </td>
###xml 207 210 203 206 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1 </td>
###xml 210 217 206 213 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> -3038 </td>
###xml 217 224 213 220 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> -2853 </td>
###xml 224 229 220 225 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 185 </td>
###xml 229 234 225 230 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 6.1 </td>
###xml 190 234 186 230 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;LTR (MaLRs) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -3038 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2853 </td><td colspan="1" rowspan="1" align="right" valign="top"> 185 </td><td colspan="1" rowspan="1" align="center" valign="top"> 6.1 </td></tr>
###xml 234 263 230 259 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;DNA element (MER1_type) </td>
###xml 263 266 259 262 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1 </td>
###xml 266 273 262 269 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> -2188 </td>
###xml 273 280 269 276 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> -2031 </td>
###xml 280 285 276 281 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 158 </td>
###xml 285 290 281 286 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 5.2 </td>
###xml 234 290 230 286 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;DNA element (MER1_type) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2188 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2031 </td><td colspan="1" rowspan="1" align="right" valign="top"> 158 </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.2 </td></tr>
###xml 290 322 286 318 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;Total interspersed repeats </td>
###xml 322 322 318 318 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 322 322 318 318 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 322 322 318 318 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 322 327 318 323 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 343 </td>
###xml 327 333 323 329 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 11.2 </td>
###xml 290 333 286 329 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;Total interspersed repeats </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"> 343 </td><td colspan="1" rowspan="1" align="center" valign="top"> 11.2 </td></tr>
###xml 333 353 329 349 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;Low complexity </td>
###xml 353 356 349 352 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1 </td>
###xml 356 361 352 357 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> -80 </td>
###xml 361 366 357 362 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> -42 </td>
###xml 366 370 362 366 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 39 </td>
###xml 370 375 366 371 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1.3 </td>
###xml 333 375 329 371 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;Low complexity </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -80 </td><td colspan="1" rowspan="1" align="right" valign="top"> -42 </td><td colspan="1" rowspan="1" align="right" valign="top"> 39 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.3 </td></tr>
###xml 128 375 128 371 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"><italic>bp</italic></td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"><bold>Human &#945;<sub>1</sub> sGC promoter repeats according to RepeatMasker</bold><xref ref-type="table-fn" rid="tblfn1"><bold><italic>a</italic></bold></xref></td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;LTR (MaLRs) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -3038 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2853 </td><td colspan="1" rowspan="1" align="right" valign="top"> 185 </td><td colspan="1" rowspan="1" align="center" valign="top"> 6.1 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;DNA element (MER1_type) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2188 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2031 </td><td colspan="1" rowspan="1" align="right" valign="top"> 158 </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.2 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;Total interspersed repeats </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"> 343 </td><td colspan="1" rowspan="1" align="center" valign="top"> 11.2 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;Low complexity </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -80 </td><td colspan="1" rowspan="1" align="right" valign="top"> -42 </td><td colspan="1" rowspan="1" align="right" valign="top"> 39 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.3 </td></tr></tbody>
###xml 385 386 378 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 375 433 371 426 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Human &#946;<sub>1</sub> sGC promoter repeats according to RepeatMasker</bold>
###xml 433 434 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 433 434 426 427 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></bold>
###xml 433 434 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn2"><bold><italic>b</italic></bold></xref>
###xml 375 434 371 427 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"><bold>Human &#946;<sub>1</sub> sGC promoter repeats according to RepeatMasker</bold><xref ref-type="table-fn" rid="tblfn2"><bold><italic>b</italic></bold></xref></td>
###xml 434 434 427 427 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 434 434 427 427 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 434 434 427 427 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 434 434 427 427 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 434 434 427 427 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 375 434 371 427 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"><bold>Human &#946;<sub>1</sub> sGC promoter repeats according to RepeatMasker</bold><xref ref-type="table-fn" rid="tblfn2"><bold><italic>b</italic></bold></xref></td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr>
###xml 434 445 427 438 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;LINE1 </td>
###xml 445 448 438 441 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1 </td>
###xml 448 455 441 448 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> -2429 </td>
###xml 455 462 448 455 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> -1671 </td>
###xml 462 467 455 460 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 759 </td>
###xml 467 473 460 466 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 22.7 </td>
###xml 434 473 427 466 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;LINE1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2429 </td><td colspan="1" rowspan="1" align="right" valign="top"> -1671 </td><td colspan="1" rowspan="1" align="right" valign="top"> 759 </td><td colspan="1" rowspan="1" align="center" valign="top"> 22.7 </td></tr>
###xml 473 505 466 498 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;Total interspersed repeats </td>
###xml 505 505 498 498 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 505 505 498 498 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 505 505 498 498 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 505 510 498 503 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 759 </td>
###xml 510 516 503 509 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 22.7 </td>
###xml 473 516 466 509 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;Total interspersed repeats </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"> 759 </td><td colspan="1" rowspan="1" align="center" valign="top"> 22.7 </td></tr>
###xml 375 516 371 509 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"><bold>Human &#946;<sub>1</sub> sGC promoter repeats according to RepeatMasker</bold><xref ref-type="table-fn" rid="tblfn2"><bold><italic>b</italic></bold></xref></td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;LINE1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2429 </td><td colspan="1" rowspan="1" align="right" valign="top"> -1671 </td><td colspan="1" rowspan="1" align="right" valign="top"> 759 </td><td colspan="1" rowspan="1" align="center" valign="top"> 22.7 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;Total interspersed repeats </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"> 759 </td><td colspan="1" rowspan="1" align="center" valign="top"> 22.7 </td></tr></tbody>
###xml 71 516 71 509 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Repeat</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>No. of elements</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Begin</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>End</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Length</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Percentage of sequence</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"><italic>bp</italic></td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"><bold>Human &#945;<sub>1</sub> sGC promoter repeats according to RepeatMasker</bold><xref ref-type="table-fn" rid="tblfn1"><bold><italic>a</italic></bold></xref></td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;LTR (MaLRs) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -3038 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2853 </td><td colspan="1" rowspan="1" align="right" valign="top"> 185 </td><td colspan="1" rowspan="1" align="center" valign="top"> 6.1 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;DNA element (MER1_type) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2188 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2031 </td><td colspan="1" rowspan="1" align="right" valign="top"> 158 </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.2 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;Total interspersed repeats </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"> 343 </td><td colspan="1" rowspan="1" align="center" valign="top"> 11.2 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;Low complexity </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -80 </td><td colspan="1" rowspan="1" align="right" valign="top"> -42 </td><td colspan="1" rowspan="1" align="right" valign="top"> 39 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.3 </td></tr></tbody><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"><bold>Human &#946;<sub>1</sub> sGC promoter repeats according to RepeatMasker</bold><xref ref-type="table-fn" rid="tblfn2"><bold><italic>b</italic></bold></xref></td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;LINE1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2429 </td><td colspan="1" rowspan="1" align="right" valign="top"> -1671 </td><td colspan="1" rowspan="1" align="right" valign="top"> 759 </td><td colspan="1" rowspan="1" align="center" valign="top"> 22.7 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;Total interspersed repeats </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"> 759 </td><td colspan="1" rowspan="1" align="center" valign="top"> 22.7 </td></tr></tbody></table>
###xml 516 517 509 510 <label xmlns:xlink="http://www.w3.org/1999/xlink">a</label>
###xml 517 586 510 579 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">Total length, 3048 bp; GC level, 36.5%; based masked, 382 bp (12.5%).</p>
###xml 516 586 509 579 <fn xmlns:xlink="http://www.w3.org/1999/xlink" id="tblfn1"><label>a</label><p textid="29">Total length, 3048 bp; GC level, 36.5%; based masked, 382 bp (12.5%).</p></fn>
###xml 586 587 579 580 <label xmlns:xlink="http://www.w3.org/1999/xlink">b</label>
###xml 587 656 580 649 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Total length, 3344 bp; GC level, 40.0%; based masked, 759 bp (22.7%).</p>
###xml 586 656 579 649 <fn xmlns:xlink="http://www.w3.org/1999/xlink" id="tblfn2"><label>b</label><p textid="30">Total length, 3344 bp; GC level, 40.0%; based masked, 759 bp (22.7%).</p></fn>
###xml 516 656 509 649 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><fn id="tblfn1"><label>a</label><p textid="29">Total length, 3048 bp; GC level, 36.5%; based masked, 382 bp (12.5%).</p></fn><fn id="tblfn2"><label>b</label><p textid="30">Total length, 3344 bp; GC level, 40.0%; based masked, 759 bp (22.7%).</p></fn></table-wrap-foot>
###xml 0 656 0 649 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="tbl1"><label>TABLE 1</label><caption><p textid="28"><bold>The positions are according to the transcription start site (+1)</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Repeat</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>No. of elements</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Begin</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>End</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Length</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Percentage of sequence</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"><italic>bp</italic></td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"><bold>Human &#945;<sub>1</sub> sGC promoter repeats according to RepeatMasker</bold><xref ref-type="table-fn" rid="tblfn1"><bold><italic>a</italic></bold></xref></td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;LTR (MaLRs) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -3038 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2853 </td><td colspan="1" rowspan="1" align="right" valign="top"> 185 </td><td colspan="1" rowspan="1" align="center" valign="top"> 6.1 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;DNA element (MER1_type) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2188 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2031 </td><td colspan="1" rowspan="1" align="right" valign="top"> 158 </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.2 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;Total interspersed repeats </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"> 343 </td><td colspan="1" rowspan="1" align="center" valign="top"> 11.2 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;Low complexity </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -80 </td><td colspan="1" rowspan="1" align="right" valign="top"> -42 </td><td colspan="1" rowspan="1" align="right" valign="top"> 39 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.3 </td></tr></tbody><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"><bold>Human &#946;<sub>1</sub> sGC promoter repeats according to RepeatMasker</bold><xref ref-type="table-fn" rid="tblfn2"><bold><italic>b</italic></bold></xref></td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;LINE1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1 </td><td colspan="1" rowspan="1" align="right" valign="top"> -2429 </td><td colspan="1" rowspan="1" align="right" valign="top"> -1671 </td><td colspan="1" rowspan="1" align="right" valign="top"> 759 </td><td colspan="1" rowspan="1" align="center" valign="top"> 22.7 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#160;&#160;&#160;&#160;Total interspersed repeats </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"> 759 </td><td colspan="1" rowspan="1" align="center" valign="top"> 22.7 </td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p textid="29">Total length, 3048 bp; GC level, 36.5%; based masked, 382 bp (12.5%).</p></fn><fn id="tblfn2"><label>b</label><p textid="30">Total length, 3344 bp; GC level, 40.0%; based masked, 759 bp (22.7%).</p></fn></table-wrap-foot></table-wrap>
###xml 375 380 <span type="species:ncbi:9606">Human</span>
TABLE 1The positions are according to the transcription start site (+1)RepeatNo. of elementsBeginEndLengthPercentage of sequencebpHuman alpha1 sGC promoter repeats according to RepeatMaskera     LTR (MaLRs)  1  -3038  -2853  185  6.1      DNA element (MER1_type)  1  -2188  -2031  158  5.2      Total interspersed repeats  343  11.2      Low complexity  1  -80  -42  39  1.3 Human beta1 sGC promoter repeats according to RepeatMaskerb     LINE1  1  -2429  -1671  759  22.7      Total interspersed repeats  759  22.7 aTotal length, 3048 bp; GC level, 36.5%; based masked, 382 bp (12.5%).bTotal length, 3344 bp; GC level, 40.0%; based masked, 759 bp (22.7%).
###end p 27
###begin p 28
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The positions are according to the transcription start site (+1)</bold>
The positions are according to the transcription start site (+1)
###end p 28
###begin p 29
Total length, 3048 bp; GC level, 36.5%; based masked, 382 bp (12.5%).
###end p 29
###begin p 30
Total length, 3344 bp; GC level, 40.0%; based masked, 759 bp (22.7%).
###end p 30
###begin p 31
###xml 0 42 0 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Analysis of Promoter Activity within the 5</italic>
###xml 43 59 43 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-Flanking Region</italic>
###xml 151 152 147 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 180 181 173 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 324 325 313 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 351 357 340 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 562 563 548 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 589 595 575 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 1273 1274 1255 1256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1283 1284 1262 1263 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 140 145 <span type="species:ncbi:9606">human</span>
###xml 170 175 <span type="species:ncbi:9606">human</span>
Analysis of Promoter Activity within the 5'-Flanking Region-Transiently transfected luciferase reporter constructs containing 0.3-3.0 kb of human alpha1 or 0.3-3.2 kb of human beta1 sGC upstream sequence were analyzed for promoter activity in HASMCs. The A0.3-kb fragment showed the highest level of activity among the alpha1 sGC promoter constructs (Fig. 1). Reduced activity in the remaining (longer) constructs suggested the presence of repressor element(s) further upstream. The B0.5- and B0.8-kb fragments showed the highest level of activity among the beta1 sGC promoter constructs (Fig. 1). The B1.4-kb fragment showed a decreased promoter activity, suggesting the presence of a repressor element(s) between -830 and -1392 bp. Extension of the promoter fragment up to 3.2 kb in length did not significantly alter the transcriptional activity of the B1.4-kb construct, suggesting the absence of net activation or repression in that region. However, the 126-bp deletion in B0.4 kb (to generate construct B0.3-kb) caused greater than 50% decrease in activity, suggesting that a key, putative enhancer(s) is located between B0.3 and B0.4-kb. In accord, the A0.3- and B0.5-kb constructs possessed the critical elements necessary for maximal promoter activity of the alpha1 and beta1 sGC promoters, respectively, and were further analyzed.
###end p 31
###begin p 32
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 41 42 37 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 44 45 40 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 55 56 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 62 63 55 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 9 95 9 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Promoter activity of human &#945;<sub>1</sub> (<italic>A</italic>) and &#946;<sub>1</sub> sGC (<italic>B</italic>) deletion constructs in HASMCs.</bold>
###xml 363 370 356 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla</italic>
###xml 449 451 442 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RU</italic>
###xml 490 491 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 505 517 494 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hatched bars</italic>
###xml 9 617 9 606 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33"><bold>Promoter activity of human &#945;<sub>1</sub> (<italic>A</italic>) and &#946;<sub>1</sub> sGC (<italic>B</italic>) deletion constructs in HASMCs.</bold> The cells were transfected with luciferase reporter constructs containing different size promoter fragments (indicated in bp relative to the transcription start site (+1)). Promoter activity of each construct was measured as firefly luciferase activity normalized to <italic>Renilla</italic> luciferase, and the results are expressed as relative luciferase light units (<italic>RU</italic>). The results are the means &#177; S.E. (<italic>n</italic> &#8805; 12). The <italic>hatched bars</italic> indicate the promoter constructs with the greatest activity. pGL3 depicts the promoter-less vector.</p>
###xml 9 617 9 606 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33"><bold>Promoter activity of human &#945;<sub>1</sub> (<italic>A</italic>) and &#946;<sub>1</sub> sGC (<italic>B</italic>) deletion constructs in HASMCs.</bold> The cells were transfected with luciferase reporter constructs containing different size promoter fragments (indicated in bp relative to the transcription start site (+1)). Promoter activity of each construct was measured as firefly luciferase activity normalized to <italic>Renilla</italic> luciferase, and the results are expressed as relative luciferase light units (<italic>RU</italic>). The results are the means &#177; S.E. (<italic>n</italic> &#8805; 12). The <italic>hatched bars</italic> indicate the promoter constructs with the greatest activity. pGL3 depicts the promoter-less vector.</p></caption>
###xml 617 617 606 606 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0310843110001"/>
###xml 0 617 0 606 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="33"><bold>Promoter activity of human &#945;<sub>1</sub> (<italic>A</italic>) and &#946;<sub>1</sub> sGC (<italic>B</italic>) deletion constructs in HASMCs.</bold> The cells were transfected with luciferase reporter constructs containing different size promoter fragments (indicated in bp relative to the transcription start site (+1)). Promoter activity of each construct was measured as firefly luciferase activity normalized to <italic>Renilla</italic> luciferase, and the results are expressed as relative luciferase light units (<italic>RU</italic>). The results are the means &#177; S.E. (<italic>n</italic> &#8805; 12). The <italic>hatched bars</italic> indicate the promoter constructs with the greatest activity. pGL3 depicts the promoter-less vector.</p></caption><graphic xlink:href="zbc0310843110001"/></fig>
###xml 30 35 <span type="species:ncbi:9606">human</span>
FIGURE 1.Promoter activity of human alpha1 (A) and beta1 sGC (B) deletion constructs in HASMCs. The cells were transfected with luciferase reporter constructs containing different size promoter fragments (indicated in bp relative to the transcription start site (+1)). Promoter activity of each construct was measured as firefly luciferase activity normalized to Renilla luciferase, and the results are expressed as relative luciferase light units (RU). The results are the means +/- S.E. (n >/= 12). The hatched bars indicate the promoter constructs with the greatest activity. pGL3 depicts the promoter-less vector.
###end p 32
###begin p 33
###xml 32 33 28 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 35 36 31 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 46 47 39 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 53 54 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 0 86 0 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Promoter activity of human &#945;<sub>1</sub> (<italic>A</italic>) and &#946;<sub>1</sub> sGC (<italic>B</italic>) deletion constructs in HASMCs.</bold>
###xml 354 361 347 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla</italic>
###xml 440 442 433 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RU</italic>
###xml 481 482 472 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 496 508 485 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hatched bars</italic>
###xml 21 26 <span type="species:ncbi:9606">human</span>
Promoter activity of human alpha1 (A) and beta1 sGC (B) deletion constructs in HASMCs. The cells were transfected with luciferase reporter constructs containing different size promoter fragments (indicated in bp relative to the transcription start site (+1)). Promoter activity of each construct was measured as firefly luciferase activity normalized to Renilla luciferase, and the results are expressed as relative luciferase light units (RU). The results are the means +/- S.E. (n >/= 12). The hatched bars indicate the promoter constructs with the greatest activity. pGL3 depicts the promoter-less vector.
###end p 33
###begin p 34
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 123 124 123 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 129 130 129 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 143 144 143 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 149 150 149 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 9 158 9 158 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Analysis of putative TFs at the proximal promoter sequence of the human sGC gene under basal conditions in HASMC (<italic>A</italic> and <italic>C</italic>) and COS-7 (<italic>B</italic> and <italic>D</italic>) cells.</bold>
###xml 158 159 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 164 165 164 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 281 282 281 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 287 288 287 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 490 497 486 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFY-1&amp;2</italic>
###xml 579 585 575 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 636 637 630 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 649 650 641 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 658 9 650 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35"><bold>Analysis of putative TFs at the proximal promoter sequence of the human sGC gene under basal conditions in HASMC (<italic>A</italic> and <italic>C</italic>) and COS-7 (<italic>B</italic> and <italic>D</italic>) cells.</bold><italic>A</italic> and <italic>B</italic>, effects of core deletions of c-Myb, GAGA, NFAT, and CCAAT-BF sites on promoter activity of the A0.3-kb construct. <italic>C</italic> and <italic>D</italic>, effects of core deletions of NF-&#954;B(p50)-, PU1-, SP1-, and NFY-binding sites on promoter activity of the B0.5-kb construct. NFY-1 and NFY-2 indicate the upstream and downstream CCAAT-BF sites with <italic>NFY-1&amp;2</italic> representing the double deletion. Promoter activity was measured as described in <xref rid="fig1" ref-type="fig">Fig. 1</xref>. The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 5). *, <italic>p</italic> &lt; 0.05.</p>
###xml 9 658 9 650 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35"><bold>Analysis of putative TFs at the proximal promoter sequence of the human sGC gene under basal conditions in HASMC (<italic>A</italic> and <italic>C</italic>) and COS-7 (<italic>B</italic> and <italic>D</italic>) cells.</bold><italic>A</italic> and <italic>B</italic>, effects of core deletions of c-Myb, GAGA, NFAT, and CCAAT-BF sites on promoter activity of the A0.3-kb construct. <italic>C</italic> and <italic>D</italic>, effects of core deletions of NF-&#954;B(p50)-, PU1-, SP1-, and NFY-binding sites on promoter activity of the B0.5-kb construct. NFY-1 and NFY-2 indicate the upstream and downstream CCAAT-BF sites with <italic>NFY-1&amp;2</italic> representing the double deletion. Promoter activity was measured as described in <xref rid="fig1" ref-type="fig">Fig. 1</xref>. The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 5). *, <italic>p</italic> &lt; 0.05.</p></caption>
###xml 658 658 650 650 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0310843110002"/>
###xml 0 658 0 650 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="35"><bold>Analysis of putative TFs at the proximal promoter sequence of the human sGC gene under basal conditions in HASMC (<italic>A</italic> and <italic>C</italic>) and COS-7 (<italic>B</italic> and <italic>D</italic>) cells.</bold><italic>A</italic> and <italic>B</italic>, effects of core deletions of c-Myb, GAGA, NFAT, and CCAAT-BF sites on promoter activity of the A0.3-kb construct. <italic>C</italic> and <italic>D</italic>, effects of core deletions of NF-&#954;B(p50)-, PU1-, SP1-, and NFY-binding sites on promoter activity of the B0.5-kb construct. NFY-1 and NFY-2 indicate the upstream and downstream CCAAT-BF sites with <italic>NFY-1&amp;2</italic> representing the double deletion. Promoter activity was measured as described in <xref rid="fig1" ref-type="fig">Fig. 1</xref>. The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 5). *, <italic>p</italic> &lt; 0.05.</p></caption><graphic xlink:href="zbc0310843110002"/></fig>
###xml 75 80 <span type="species:ncbi:9606">human</span>
FIGURE 2.Analysis of putative TFs at the proximal promoter sequence of the human sGC gene under basal conditions in HASMC (A and C) and COS-7 (B and D) cells.A and B, effects of core deletions of c-Myb, GAGA, NFAT, and CCAAT-BF sites on promoter activity of the A0.3-kb construct. C and D, effects of core deletions of NF-kappaB(p50)-, PU1-, SP1-, and NFY-binding sites on promoter activity of the B0.5-kb construct. NFY-1 and NFY-2 indicate the upstream and downstream CCAAT-BF sites with NFY-1&2 representing the double deletion. Promoter activity was measured as described in Fig. 1. The results are expressed as the means +/- S.E. (n >/= 5). *, p < 0.05.
###end p 34
###begin p 35
###xml 114 115 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 120 121 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 134 135 134 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 140 141 140 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 0 149 0 149 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Analysis of putative TFs at the proximal promoter sequence of the human sGC gene under basal conditions in HASMC (<italic>A</italic> and <italic>C</italic>) and COS-7 (<italic>B</italic> and <italic>D</italic>) cells.</bold>
###xml 149 150 149 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 155 156 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 272 273 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 278 279 278 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 481 488 477 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFY-1&amp;2</italic>
###xml 570 576 566 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 627 628 621 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 640 641 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 66 71 <span type="species:ncbi:9606">human</span>
Analysis of putative TFs at the proximal promoter sequence of the human sGC gene under basal conditions in HASMC (A and C) and COS-7 (B and D) cells.A and B, effects of core deletions of c-Myb, GAGA, NFAT, and CCAAT-BF sites on promoter activity of the A0.3-kb construct. C and D, effects of core deletions of NF-kappaB(p50)-, PU1-, SP1-, and NFY-binding sites on promoter activity of the B0.5-kb construct. NFY-1 and NFY-2 indicate the upstream and downstream CCAAT-BF sites with NFY-1&2 representing the double deletion. Promoter activity was measured as described in Fig. 1. The results are expressed as the means +/- S.E. (n >/= 5). *, p < 0.05.
###end p 35
###begin p 36
###xml 274 278 274 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 73 78 <span type="species:ncbi:10090">mouse</span>
###xml 83 86 <span type="species:ncbi:10116">rat</span>
###xml 180 183 <span type="species:ncbi:10116">rat</span>
###xml 381 386 <span type="species:ncbi:9606">human</span>
###xml 399 404 <span type="species:ncbi:9606">human</span>
Interestingly, the A0.3-kb sequence exhibited only 44% homology with the mouse and rat sequence homologues and the B0.5-kb fragment possessed a 57% homology when compared with the rat sequence. As a consequence, there is likely to be disparate regulation of sGC expression (i.e. promoter activity) between species, highlighting the importance of characterizing the activity of the human promoter in human cells.
###end p 36
###begin p 37
###xml 0 54 0 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Identification of Critical Transcription Binding Sites</italic>
###xml 188 189 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 198 199 191 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 347 348 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 354 355 347 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 672 673 661 662 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 682 683 668 669 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1173 1174 1159 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1181 1182 1163 1164 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1194 1195 1176 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1201 1202 1180 1181 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 177 182 <span type="species:ncbi:9606">human</span>
Identification of Critical Transcription Binding Sites-Analysis of putative transcription factor-binding sites in the fragments containing the maximal promoter activity for the human alpha1 and beta1 sGC genes was performed using MatInspector software (solution parameters: core similarity, 1.0; matrix similarity optimized) (supplemental Figs. S4A and 5A) and confirmed by Transcription Element Search Software. In both A0.3-kb and B0.5-kb constructs, putative TF-binding sites for several transcription factors located at the optimal regulatory distance from the transcription start site were investigated. To functionally determine the importance of these TFs for alpha1 and beta1 sGC promoter activity, the cores of each TF-binding site were deleted individually in both the A0.3-kb and B0.5-kb basal constructs via site-directed mutagenesis. These deletions did not introduce any new binding sites as confirmed by sequence analysis with MatInspector software. Transcriptional activity of these mutant constructs was assessed in HASMCs and COS-7 cells; TF-binding sites that had a significant effect on sGC promoter activity in HASMCs are shown in supplemental Figs. S4B (alpha1 sGC) and S5B (beta1 sGC).
###end p 37
###begin p 38
###xml 188 189 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 182 189 182 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 286 287 282 283 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 418 419 414 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 412 419 408 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 501 502 497 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 495 502 491 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 694 695 686 687 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
A0.3-kb fragments harboring deletions for CCAAT-BF-, c-Myb-, GAGA-, and NFAT-binding sites showed significant increases in promoter activity compared with A0.3-kb control in HASMCs (Fig. 2A), suggesting that binding of these TFs to their recognition sites has repressor effects on alpha1 sGC promoter activity in these cells. The effect of c-Myb was abolished in COS-7 cells, suggesting a HASMC-specific effect (Fig. 2B). Moreover, the effects of GAGA and NFAT were also reduced in COS-7 cells (Fig. 2B), despite still having significant repressor activity. However, CCAAT-BF had a similar effect in COS-7 cells, suggesting that this TF may belong to the basal transcription machinery for alpha1 sGC gene in many cell types.
###end p 38
###begin p 39
###xml 171 172 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 165 172 161 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 217 218 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 211 218 207 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 310 311 299 300 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 542 543 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 536 543 525 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 608 609 597 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 602 609 591 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 655 657 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 624 629 <span type="species:ncbi:9606">human</span>
B0.5-kb fragments harboring a deletion for an NF-kappaB(p50)-binding site showed almost 2-fold increase in promoter activity compared with B0.5kb control in HASMCs (Fig. 2C). This effect was identical in COS-7 (Fig. 2D), suggesting that NF-kappaB(p50) plays a key repressor role in the basal expression of beta1 sGC, independent of cell type. In contrast, a B0.5-kb fragment harboring deletions for both NFY-binding sites showed a small reduction in B0.5-kb promoter activity in HASMCs, suggesting a slight activator effect of this TF (Fig. 2C). The activator effect of NFY was much stronger in COS-7 (Fig. 2D) and in a BE2 human neuroblastoma cell line (34), suggesting that a cell-specific effect of NFY is not so apparent in HASMC. PU1 and SP1 TFs showed activator and repressor effects, respectively, in COS-7 cells but not in HASMCs, again suggesting cell-specific regulation of sGC promoter activity.
###end p 39
###begin p 40
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 116 126 116 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Black bars</italic>
###xml 146 156 146 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">empty bars</italic>
###xml 248 254 248 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 305 306 303 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 318 319 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 328 329 324 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 353 354 346 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 547 548 540 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 664 665 657 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 676 677 669 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 685 691 678 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 9 762 9 755 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">Temporal effects of a pro-inflammatory mixture on A0.3-kb (A) and B0.5-kb (B) promoter activity in HASMCs. <italic>Black bars</italic>, basal conditions; <italic>empty bars</italic>, pro-inflammatory conditions. Promoter activity was measured as described in the legend to <xref rid="fig1" ref-type="fig">Fig. 1</xref>. The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 3). *, <italic>p</italic> &lt; 0.05. <italic>C</italic>, expression of sGC &#946;<sub>1</sub> protein determined by Western blot in HASMC under basal and pro-inflammatory conditions (0&#8211;48 h of incubation with mixture). The data are representative of at least three similar experiments. <italic>D</italic>, basal and NO-stimulated increases in cGMP in HASMC in the absence and presence of pro-inflammatory mixture (24 h; <italic>n</italic> = 40). *, <italic>p</italic> &lt; 0.05 <italic>versus</italic> the corresponding response in the absence of pro-inflammatory mixture.</p>
###xml 9 762 9 755 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="41">Temporal effects of a pro-inflammatory mixture on A0.3-kb (A) and B0.5-kb (B) promoter activity in HASMCs. <italic>Black bars</italic>, basal conditions; <italic>empty bars</italic>, pro-inflammatory conditions. Promoter activity was measured as described in the legend to <xref rid="fig1" ref-type="fig">Fig. 1</xref>. The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 3). *, <italic>p</italic> &lt; 0.05. <italic>C</italic>, expression of sGC &#946;<sub>1</sub> protein determined by Western blot in HASMC under basal and pro-inflammatory conditions (0&#8211;48 h of incubation with mixture). The data are representative of at least three similar experiments. <italic>D</italic>, basal and NO-stimulated increases in cGMP in HASMC in the absence and presence of pro-inflammatory mixture (24 h; <italic>n</italic> = 40). *, <italic>p</italic> &lt; 0.05 <italic>versus</italic> the corresponding response in the absence of pro-inflammatory mixture.</p></caption>
###xml 762 762 755 755 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0310843110003"/>
###xml 0 762 0 755 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="41">Temporal effects of a pro-inflammatory mixture on A0.3-kb (A) and B0.5-kb (B) promoter activity in HASMCs. <italic>Black bars</italic>, basal conditions; <italic>empty bars</italic>, pro-inflammatory conditions. Promoter activity was measured as described in the legend to <xref rid="fig1" ref-type="fig">Fig. 1</xref>. The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 3). *, <italic>p</italic> &lt; 0.05. <italic>C</italic>, expression of sGC &#946;<sub>1</sub> protein determined by Western blot in HASMC under basal and pro-inflammatory conditions (0&#8211;48 h of incubation with mixture). The data are representative of at least three similar experiments. <italic>D</italic>, basal and NO-stimulated increases in cGMP in HASMC in the absence and presence of pro-inflammatory mixture (24 h; <italic>n</italic> = 40). *, <italic>p</italic> &lt; 0.05 <italic>versus</italic> the corresponding response in the absence of pro-inflammatory mixture.</p></caption><graphic xlink:href="zbc0310843110003"/></fig>
FIGURE 3.Temporal effects of a pro-inflammatory mixture on A0.3-kb (A) and B0.5-kb (B) promoter activity in HASMCs. Black bars, basal conditions; empty bars, pro-inflammatory conditions. Promoter activity was measured as described in the legend to Fig. 1. The results are expressed as the means +/- S.E. (n >/= 3). *, p < 0.05. C, expression of sGC beta1 protein determined by Western blot in HASMC under basal and pro-inflammatory conditions (0-48 h of incubation with mixture). The data are representative of at least three similar experiments. D, basal and NO-stimulated increases in cGMP in HASMC in the absence and presence of pro-inflammatory mixture (24 h; n = 40). *, p < 0.05 versus the corresponding response in the absence of pro-inflammatory mixture.
###end p 40
###begin p 41
###xml 107 117 107 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Black bars</italic>
###xml 137 147 137 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">empty bars</italic>
###xml 239 245 239 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 296 297 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 309 310 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 319 320 315 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 344 345 337 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 538 539 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 655 656 648 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 667 668 660 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 676 682 669 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
Temporal effects of a pro-inflammatory mixture on A0.3-kb (A) and B0.5-kb (B) promoter activity in HASMCs. Black bars, basal conditions; empty bars, pro-inflammatory conditions. Promoter activity was measured as described in the legend to Fig. 1. The results are expressed as the means +/- S.E. (n >/= 3). *, p < 0.05. C, expression of sGC beta1 protein determined by Western blot in HASMC under basal and pro-inflammatory conditions (0-48 h of incubation with mixture). The data are representative of at least three similar experiments. D, basal and NO-stimulated increases in cGMP in HASMC in the absence and presence of pro-inflammatory mixture (24 h; n = 40). *, p < 0.05 versus the corresponding response in the absence of pro-inflammatory mixture.
###end p 41
###begin p 42
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 4.</label>
###xml 572 573 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 625 626 603 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 638 639 614 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 647 9 623 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="43">Electrophoretic mobility shift assay (A and B) with densitometric quantification (C and D) of HASMC nuclear extracts under basal and pro-inflammatory conditions (2h of incubation with the mixture) was performed using labeled primers carrying the NF-&#954;B or CCAAT-BF binding sites or the mutated version (&#916;NF-&#954;Bor &#916;CCAAT-BF). For competition experiments, a 100&#215; excess of unlabeled double-stranded oligonucleotide (cold probe) was added to the binding reaction. A supershift at the NF-&#954;B site was demonstrable using a p50, but not p65, antibody (<italic>E</italic>). The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 3). *, <italic>p</italic> &lt; 0.05.</p>
###xml 9 647 9 623 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="43">Electrophoretic mobility shift assay (A and B) with densitometric quantification (C and D) of HASMC nuclear extracts under basal and pro-inflammatory conditions (2h of incubation with the mixture) was performed using labeled primers carrying the NF-&#954;B or CCAAT-BF binding sites or the mutated version (&#916;NF-&#954;Bor &#916;CCAAT-BF). For competition experiments, a 100&#215; excess of unlabeled double-stranded oligonucleotide (cold probe) was added to the binding reaction. A supershift at the NF-&#954;B site was demonstrable using a p50, but not p65, antibody (<italic>E</italic>). The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 3). *, <italic>p</italic> &lt; 0.05.</p></caption>
###xml 647 647 623 623 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0310843110004"/>
###xml 0 647 0 623 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig4"><label>FIGURE 4.</label><caption><p textid="43">Electrophoretic mobility shift assay (A and B) with densitometric quantification (C and D) of HASMC nuclear extracts under basal and pro-inflammatory conditions (2h of incubation with the mixture) was performed using labeled primers carrying the NF-&#954;B or CCAAT-BF binding sites or the mutated version (&#916;NF-&#954;Bor &#916;CCAAT-BF). For competition experiments, a 100&#215; excess of unlabeled double-stranded oligonucleotide (cold probe) was added to the binding reaction. A supershift at the NF-&#954;B site was demonstrable using a p50, but not p65, antibody (<italic>E</italic>). The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 3). *, <italic>p</italic> &lt; 0.05.</p></caption><graphic xlink:href="zbc0310843110004"/></fig>
FIGURE 4.Electrophoretic mobility shift assay (A and B) with densitometric quantification (C and D) of HASMC nuclear extracts under basal and pro-inflammatory conditions (2h of incubation with the mixture) was performed using labeled primers carrying the NF-kappaB or CCAAT-BF binding sites or the mutated version (DeltaNF-kappaBor DeltaCCAAT-BF). For competition experiments, a 100x excess of unlabeled double-stranded oligonucleotide (cold probe) was added to the binding reaction. A supershift at the NF-kappaB site was demonstrable using a p50, but not p65, antibody (E). The results are expressed as the means +/- S.E. (n >/= 3). *, p < 0.05.
###end p 42
###begin p 43
###xml 563 564 543 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 616 617 594 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 629 630 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Electrophoretic mobility shift assay (A and B) with densitometric quantification (C and D) of HASMC nuclear extracts under basal and pro-inflammatory conditions (2h of incubation with the mixture) was performed using labeled primers carrying the NF-kappaB or CCAAT-BF binding sites or the mutated version (DeltaNF-kappaBor DeltaCCAAT-BF). For competition experiments, a 100x excess of unlabeled double-stranded oligonucleotide (cold probe) was added to the binding reaction. A supershift at the NF-kappaB site was demonstrable using a p50, but not p65, antibody (E). The results are expressed as the means +/- S.E. (n >/= 3). *, p < 0.05.
###end p 43
###begin p 44
###xml 0 72 0 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Effect of Pro-inflammatory Conditions on sGC Promoter Activity in HASMCs</italic>
###xml 161 162 157 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 171 172 164 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 279 280 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 273 280 266 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 301 302 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 295 302 288 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 380 381 369 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 390 391 376 377 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 508 509 491 492 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 592 593 575 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 586 593 569 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 696 697 679 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 690 697 673 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>D</italic></xref>
###xml 150 155 <span type="species:ncbi:9606">human</span>
Effect of Pro-inflammatory Conditions on sGC Promoter Activity in HASMCs-To examine whether vascular inflammation modulates sGC expression in HASMCs, human alpha1 and beta1 sGC promoter activity was examined in the presence of a pro-inflammatory mixture using the A0.3-kb (Fig. 3A) and B0.5-kB (Fig. 3B) constructs. Pro-inflammatory conditions significantly reduced both the alpha1 and beta1 sGC promoter activity at 24 h. Moreover, Western blot analysis revealed a clear, time-dependent decrease in sGC beta1 expression following exposure of the HASMC to the pro-inflammatory mixture (Fig. 3C) that was mirrored by a significant reduction in both the basal and NO-stimulated sGC activity (Fig. 3D).
###end p 44
###begin p 45
###xml 12 18 12 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 86 87 78 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 96 97 85 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 330 331 315 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 517 518 502 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 511 518 496 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 849 850 834 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 843 850 828 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 946 947 927 928 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 987 988 968 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 990 991 971 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
As shown in Fig. 2, CCAAT-BF and NF-kappaB exerted the most pronounced effect on alpha1 and beta1 sGC promoter activity, respectively, among the TFs studied. To determine whether these transcription factors bind to the target DNA sequences on the promoter, nuclear extracts from HASMCs were analyzed by EMSA. In terms of the alpha1 sGC promoter, three complexes were detected using the oligonucleotide probe containing -93 to -66 bp region (CCAAT-BF oligonucleotide) upstream of the transcriptional start site (Fig. 4A). The specificity of these complexes was demonstrated by a reduction of the intensity of all three bands in the presence of an excess of unlabeled probe. When the nuclear extract derived from HASMCs treated with the pro-inflammatory mixture was analyzed, an increase in the intensity of two of these complexes was observed (Fig. 4C), suggesting that vascular inflammation increased the binding of CCAAT-BF to the proximal alpha1 sGC promoter. The deletion of a single c (g) of the core of the CCAAT-BF site (position -82; supplemental Fig. S4) abolished the formation of two of the three complexes, highlighting the importance of that single base for the binding of the CCAAT-BF to the target promoter.
###end p 45
###begin p 46
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 5.</label>
###xml 25 26 25 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 31 32 31 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 45 46 45 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 51 52 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 105 106 104 105 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 139 140 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 145 146 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 158 159 157 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 164 165 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 9 195 9 194 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Concentration- (<italic>A</italic> and <italic>B</italic>) and time- (<italic>C</italic> and <italic>D</italic>) dependent effects of the NO donor DETA-NO (0&#8211;200 &#956;<sc>m</sc> and 0&#8211;48-h incubation) on A0.3 (<italic>A</italic> and <italic>C</italic>) and B0.5 (<italic>B</italic> and <italic>D</italic>) promoter activity in HASMCs.</bold>
###xml 257 263 256 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 314 315 311 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 327 328 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 336 342 331 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 9 378 9 373 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47"><bold>Concentration- (<italic>A</italic> and <italic>B</italic>) and time- (<italic>C</italic> and <italic>D</italic>) dependent effects of the NO donor DETA-NO (0&#8211;200 &#956;<sc>m</sc> and 0&#8211;48-h incubation) on A0.3 (<italic>A</italic> and <italic>C</italic>) and B0.5 (<italic>B</italic> and <italic>D</italic>) promoter activity in HASMCs.</bold> Promoter activity was measured as described in the legend to <xref rid="fig1" ref-type="fig">Fig. 1</xref>. The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 3). *, <italic>p</italic> &lt; 0.05 <italic>versus</italic> response in the absence of DETA-NO.</p>
###xml 9 378 9 373 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="47"><bold>Concentration- (<italic>A</italic> and <italic>B</italic>) and time- (<italic>C</italic> and <italic>D</italic>) dependent effects of the NO donor DETA-NO (0&#8211;200 &#956;<sc>m</sc> and 0&#8211;48-h incubation) on A0.3 (<italic>A</italic> and <italic>C</italic>) and B0.5 (<italic>B</italic> and <italic>D</italic>) promoter activity in HASMCs.</bold> Promoter activity was measured as described in the legend to <xref rid="fig1" ref-type="fig">Fig. 1</xref>. The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 3). *, <italic>p</italic> &lt; 0.05 <italic>versus</italic> response in the absence of DETA-NO.</p></caption>
###xml 378 378 373 373 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0310843110005"/>
###xml 0 378 0 373 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig5"><label>FIGURE 5.</label><caption><p textid="47"><bold>Concentration- (<italic>A</italic> and <italic>B</italic>) and time- (<italic>C</italic> and <italic>D</italic>) dependent effects of the NO donor DETA-NO (0&#8211;200 &#956;<sc>m</sc> and 0&#8211;48-h incubation) on A0.3 (<italic>A</italic> and <italic>C</italic>) and B0.5 (<italic>B</italic> and <italic>D</italic>) promoter activity in HASMCs.</bold> Promoter activity was measured as described in the legend to <xref rid="fig1" ref-type="fig">Fig. 1</xref>. The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 3). *, <italic>p</italic> &lt; 0.05 <italic>versus</italic> response in the absence of DETA-NO.</p></caption><graphic xlink:href="zbc0310843110005"/></fig>
FIGURE 5.Concentration- (A and B) and time- (C and D) dependent effects of the NO donor DETA-NO (0-200 mum and 0-48-h incubation) on A0.3 (A and C) and B0.5 (B and D) promoter activity in HASMCs. Promoter activity was measured as described in the legend to Fig. 1. The results are expressed as the means +/- S.E. (n >/= 3). *, p < 0.05 versus response in the absence of DETA-NO.
###end p 46
###begin p 47
###xml 16 17 16 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 22 23 22 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 36 37 36 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 42 43 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 96 97 95 96 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 130 131 129 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 136 137 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 149 150 148 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 155 156 154 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 0 186 0 185 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Concentration- (<italic>A</italic> and <italic>B</italic>) and time- (<italic>C</italic> and <italic>D</italic>) dependent effects of the NO donor DETA-NO (0&#8211;200 &#956;<sc>m</sc> and 0&#8211;48-h incubation) on A0.3 (<italic>A</italic> and <italic>C</italic>) and B0.5 (<italic>B</italic> and <italic>D</italic>) promoter activity in HASMCs.</bold>
###xml 248 254 247 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 305 306 302 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 318 319 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 327 333 322 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
Concentration- (A and B) and time- (C and D) dependent effects of the NO donor DETA-NO (0-200 mum and 0-48-h incubation) on A0.3 (A and C) and B0.5 (B and D) promoter activity in HASMCs. Promoter activity was measured as described in the legend to Fig. 1. The results are expressed as the means +/- S.E. (n >/= 3). *, p < 0.05 versus response in the absence of DETA-NO.
###end p 47
###begin p 48
###xml 12 13 9 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 209 210 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 427 428 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 421 428 406 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 552 553 537 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 546 553 531 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>E</italic></xref>
###xml 664 665 642 643 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 744 745 719 720 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 906 908 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref38">38</xref>
###xml 910 912 885 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref39">39</xref>
###xml 1086 1087 1061 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1080 1087 1055 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>D</italic></xref>
###xml 1199 1200 1167 1168 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1246 1250 1214 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gggg</italic>
###xml 1395 1399 1359 1363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gggg</italic>
###xml 1529 1530 1486 1487 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1628 1629 1585 1586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1634 1635 1591 1592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1620 1635 1577 1592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, <italic>C</italic> and <italic>D</italic></xref>
For the beta1 sGC promoter, interactions within the NF-kappaB(p50)-binding region were also assessed using a NF-kappaB oligonucleotide encompassing -138 to -109 bp region of this promoter (supplemental Fig. S5B). Three complexes were formed after incubation of the NF-kappaB probe with HASMC nuclear extracts. These complexes were no longer formed in the presence of an excess of unlabeled probe, confirming specificity (Fig. 4B). Interestingly, a supershift of the complexes was only observed when we used an anti-p50 antibody but not anti-p65 (Fig. 4E), suggesting that the smaller NF-kappaB subunit (perhaps as a p50 homodimer) is pivotal in regulating sGC beta1 expression; this finding dovetails well with the observed increase in sGC beta1 promoter activity in the construct with deleted p50 consensus site(s) and with previous reports detailing a predominantly repressor activity of p50 homodimers (38, 39). When the nuclear extract derived from HASMCs treated with the pro-inflammatory mixture was analyzed, an increase in the intensity of the complex bands was observed (Fig. 4D), suggesting that vascular inflammation increased the binding of the NF-kappaB(p50) factor to the proximal beta1 sGC promoter. The deletion of the 4-bp core (gggg) for the NF-kappaB factor-binding site disrupted the formation of two complexes and reduced the formation of the third one, indicating that the gggg motif is necessary for its DNA interaction. Furthermore, an important role for NF-kappaB in regulating the expression of the beta1 subunit was supported by a parallel reduction in enzyme protein expression and activity (Fig. 3, C and D).
###end p 48
###begin p 49
###xml 0 47 0 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Effect of NO on sGC Promoter Activity in HASMCs</italic>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref40">40</xref>
###xml 277 278 273 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 287 288 280 281 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 417 419 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref41">41</xref>
###xml 464 465 453 454 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 653 654 639 640 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 883 889 869 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 962 963 944 945 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 972 973 951 952 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1030 1031 1008 1009 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1106 1107 1084 1085 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1109 1111 1087 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref42">42</xref>
###xml 1294 1300 1272 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 266 271 <span type="species:ncbi:9606">human</span>
Effect of NO on sGC Promoter Activity in HASMCs-To assess the effect of the sGC ligand NO on expression of the enzyme in HASMCs (to establish the existence of a feedback loop in terms of enzyme expression, which is well established to occur biochemically (30, 40)), human alpha1 and beta1 sGC promoter activity was examined in the presence of the NO donor DETA-NONOate (releases NO spontaneously in aqueous solution (41)). Pilot studies revealed that for the alpha1 subunit, the promoter activity was inhibited to the greatest extent in the A0.3 construct, suggesting that key NO-dependent repressors are located in this region of the promoter. For beta1 sGC, maximal inhibition was observed in the B0.5 construct, suggesting that this area of the promoter contains the critical NO-responsive repressor element(s). Subsequent studies were therefore conducted using these constructs. Fig. 5 shows that NO exerted a concentration-dependent inhibition of both alpha1 and beta1 sGC promoter activity. This effect was maximal at 200 mum DETA-NO, which results in an approximate ambient NO concentration of 200 nm (42). Moreover, the inhibition of promoter activity by NO followed a time course very similar to that observed under pro-inflammatory conditions with maximal effect observed at 24-48 h (Fig. 5).
###end p 49
###begin p 50
###xml 238 239 234 235 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 248 249 241 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 324 325 316 317 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 378 379 369 370 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 389 390 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 395 396 386 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 381 396 372 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6, <italic>A</italic> and <italic>B</italic></xref>
To determine whether the repressor activity of NO was cGMP-dependent or independent, further experiments were conducted using the A0.3 and B0.5 constructs as models of promoter function. Here, the NO-dependent inhibition of both the alpha1 and beta1 sGC promoter was not reversed in the presence of the sGC blocker ODQ (5 mum) nor mimicked by the cGMP analogue 8-Br-cGMP (300 mum; Fig. 6, A and B). Thus, it appears that the inhibitory effect of NO on sGC promoter activity and expression is mediated directly, rather than via activation of the enzyme (and cGMP production).
###end p 50
###begin p 51
###xml 364 365 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 358 365 358 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>C</italic></xref>
In an attempt to identify putative transcription factors that might mediate the repressor effects of NO, A0.3, and B0.5 constructs with targeted mutations in specific TF-binding sites were analyzed for their responsiveness to NO. Interestingly, the activity of the A0.3 fragment with a deleted CCAAT-BF site was no longer sensitive to inhibition by DETA-NO (Fig. 6C), intimating that this response element is involved in mediating the negative feedback effect of NO on sGC expression. In contrast, deletion of the same site in the B0.5 construct did not alter promoter activity in the presence of NO.
###end p 51
###begin p 52
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 6.</label>
###xml 46 47 45 46 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 83 84 81 82 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 156 157 153 154 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 199 200 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 205 206 202 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 218 219 215 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 224 225 221 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 9 254 9 251 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of the sGC inhibitor ODQ (5 &#956;<sc>m</sc>) and cGMP analogue 8Br-cGMP (300 &#956;<sc>m</sc>) and core deletions of CCAAT-BF and NFY on NO-mediated (DETA-NO, 200 &#956;<sc>m</sc>; 24 h of incubation) inhibition of A0.3 (<italic>A</italic> and <italic>C</italic>) and B0.5 (<italic>B</italic> and <italic>D</italic>) promoter activity in HASMC.</bold>
###xml 316 322 313 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 373 374 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 386 387 379 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 395 401 388 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 425 426 418 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 434 440 427 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 457 458 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 463 464 456 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 9 529 9 522 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="53"><bold>Effect of the sGC inhibitor ODQ (5 &#956;<sc>m</sc>) and cGMP analogue 8Br-cGMP (300 &#956;<sc>m</sc>) and core deletions of CCAAT-BF and NFY on NO-mediated (DETA-NO, 200 &#956;<sc>m</sc>; 24 h of incubation) inhibition of A0.3 (<italic>A</italic> and <italic>C</italic>) and B0.5 (<italic>B</italic> and <italic>D</italic>) promoter activity in HASMC.</bold> Promoter activity was measured as described in the legend to <xref rid="fig1" ref-type="fig">Fig. 1</xref>. The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 3). *, <italic>p</italic> &lt; 0.05 <italic>versus</italic> respective control. #, <italic>p</italic> &lt; 0.05 <italic>versus</italic> A0.3 + DETA. In <italic>C</italic> and <italic>D</italic>, promoter activity in the absence of DETA is normalized to 100%.</p>
###xml 9 529 9 522 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="53"><bold>Effect of the sGC inhibitor ODQ (5 &#956;<sc>m</sc>) and cGMP analogue 8Br-cGMP (300 &#956;<sc>m</sc>) and core deletions of CCAAT-BF and NFY on NO-mediated (DETA-NO, 200 &#956;<sc>m</sc>; 24 h of incubation) inhibition of A0.3 (<italic>A</italic> and <italic>C</italic>) and B0.5 (<italic>B</italic> and <italic>D</italic>) promoter activity in HASMC.</bold> Promoter activity was measured as described in the legend to <xref rid="fig1" ref-type="fig">Fig. 1</xref>. The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 3). *, <italic>p</italic> &lt; 0.05 <italic>versus</italic> respective control. #, <italic>p</italic> &lt; 0.05 <italic>versus</italic> A0.3 + DETA. In <italic>C</italic> and <italic>D</italic>, promoter activity in the absence of DETA is normalized to 100%.</p></caption>
###xml 529 529 522 522 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0310843110006"/>
###xml 0 529 0 522 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig6"><label>FIGURE 6.</label><caption><p textid="53"><bold>Effect of the sGC inhibitor ODQ (5 &#956;<sc>m</sc>) and cGMP analogue 8Br-cGMP (300 &#956;<sc>m</sc>) and core deletions of CCAAT-BF and NFY on NO-mediated (DETA-NO, 200 &#956;<sc>m</sc>; 24 h of incubation) inhibition of A0.3 (<italic>A</italic> and <italic>C</italic>) and B0.5 (<italic>B</italic> and <italic>D</italic>) promoter activity in HASMC.</bold> Promoter activity was measured as described in the legend to <xref rid="fig1" ref-type="fig">Fig. 1</xref>. The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 3). *, <italic>p</italic> &lt; 0.05 <italic>versus</italic> respective control. #, <italic>p</italic> &lt; 0.05 <italic>versus</italic> A0.3 + DETA. In <italic>C</italic> and <italic>D</italic>, promoter activity in the absence of DETA is normalized to 100%.</p></caption><graphic xlink:href="zbc0310843110006"/></fig>
FIGURE 6.Effect of the sGC inhibitor ODQ (5 mum) and cGMP analogue 8Br-cGMP (300 mum) and core deletions of CCAAT-BF and NFY on NO-mediated (DETA-NO, 200 mum; 24 h of incubation) inhibition of A0.3 (A and C) and B0.5 (B and D) promoter activity in HASMC. Promoter activity was measured as described in the legend to Fig. 1. The results are expressed as the means +/- S.E. (n >/= 3). *, p < 0.05 versus respective control. #, p < 0.05 versus A0.3 + DETA. In C and D, promoter activity in the absence of DETA is normalized to 100%.
###end p 52
###begin p 53
###xml 37 38 36 37 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 74 75 72 73 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 147 148 144 145 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 190 191 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 196 197 193 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 209 210 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 215 216 212 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 0 245 0 242 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of the sGC inhibitor ODQ (5 &#956;<sc>m</sc>) and cGMP analogue 8Br-cGMP (300 &#956;<sc>m</sc>) and core deletions of CCAAT-BF and NFY on NO-mediated (DETA-NO, 200 &#956;<sc>m</sc>; 24 h of incubation) inhibition of A0.3 (<italic>A</italic> and <italic>C</italic>) and B0.5 (<italic>B</italic> and <italic>D</italic>) promoter activity in HASMC.</bold>
###xml 307 313 304 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 364 365 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 377 378 370 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 386 392 379 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 416 417 409 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 425 431 418 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 448 449 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 454 455 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
Effect of the sGC inhibitor ODQ (5 mum) and cGMP analogue 8Br-cGMP (300 mum) and core deletions of CCAAT-BF and NFY on NO-mediated (DETA-NO, 200 mum; 24 h of incubation) inhibition of A0.3 (A and C) and B0.5 (B and D) promoter activity in HASMC. Promoter activity was measured as described in the legend to Fig. 1. The results are expressed as the means +/- S.E. (n >/= 3). *, p < 0.05 versus respective control. #, p < 0.05 versus A0.3 + DETA. In C and D, promoter activity in the absence of DETA is normalized to 100%.
###end p 53
###begin p 54
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 7.</label>
###xml 47 48 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 85 86 85 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 166 167 165 166 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 9 295 9 290 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electrophoretic mobility shift assay (<italic>A</italic>) with densitometric quantification (<italic>B</italic>) of HASMC nuclear extracts under basal conditions and in the presence of 100 &#956;<sc>m</sc> DETA-NO (2-h incubation) was performed using labeled primers carrying the CCAAT-BF site or its mutated version (&#916;CCAAT-BF).</bold>
###xml 482 483 475 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 495 496 486 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 504 9 495 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="55"><bold>Electrophoretic mobility shift assay (<italic>A</italic>) with densitometric quantification (<italic>B</italic>) of HASMC nuclear extracts under basal conditions and in the presence of 100 &#956;<sc>m</sc> DETA-NO (2-h incubation) was performed using labeled primers carrying the CCAAT-BF site or its mutated version (&#916;CCAAT-BF).</bold> For competition experiments, a 100&#215; excess of unlabeled doubled-stranded oligonucleotide (cold probe) was added to the binding reaction. The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 3). *, <italic>p</italic> &lt; 0.05.</p>
###xml 9 504 9 495 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="55"><bold>Electrophoretic mobility shift assay (<italic>A</italic>) with densitometric quantification (<italic>B</italic>) of HASMC nuclear extracts under basal conditions and in the presence of 100 &#956;<sc>m</sc> DETA-NO (2-h incubation) was performed using labeled primers carrying the CCAAT-BF site or its mutated version (&#916;CCAAT-BF).</bold> For competition experiments, a 100&#215; excess of unlabeled doubled-stranded oligonucleotide (cold probe) was added to the binding reaction. The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 3). *, <italic>p</italic> &lt; 0.05.</p></caption>
###xml 504 504 495 495 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0310843110007"/>
###xml 0 504 0 495 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig7"><label>FIGURE 7.</label><caption><p textid="55"><bold>Electrophoretic mobility shift assay (<italic>A</italic>) with densitometric quantification (<italic>B</italic>) of HASMC nuclear extracts under basal conditions and in the presence of 100 &#956;<sc>m</sc> DETA-NO (2-h incubation) was performed using labeled primers carrying the CCAAT-BF site or its mutated version (&#916;CCAAT-BF).</bold> For competition experiments, a 100&#215; excess of unlabeled doubled-stranded oligonucleotide (cold probe) was added to the binding reaction. The results are expressed as the means &#177; S.E. (<italic>n</italic> &#8805; 3). *, <italic>p</italic> &lt; 0.05.</p></caption><graphic xlink:href="zbc0310843110007"/></fig>
FIGURE 7.Electrophoretic mobility shift assay (A) with densitometric quantification (B) of HASMC nuclear extracts under basal conditions and in the presence of 100 mum DETA-NO (2-h incubation) was performed using labeled primers carrying the CCAAT-BF site or its mutated version (DeltaCCAAT-BF). For competition experiments, a 100x excess of unlabeled doubled-stranded oligonucleotide (cold probe) was added to the binding reaction. The results are expressed as the means +/- S.E. (n >/= 3). *, p < 0.05.
###end p 54
###begin p 55
###xml 38 39 38 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 76 77 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 157 158 156 157 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 0 286 0 281 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electrophoretic mobility shift assay (<italic>A</italic>) with densitometric quantification (<italic>B</italic>) of HASMC nuclear extracts under basal conditions and in the presence of 100 &#956;<sc>m</sc> DETA-NO (2-h incubation) was performed using labeled primers carrying the CCAAT-BF site or its mutated version (&#916;CCAAT-BF).</bold>
###xml 473 474 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 486 487 477 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Electrophoretic mobility shift assay (A) with densitometric quantification (B) of HASMC nuclear extracts under basal conditions and in the presence of 100 mum DETA-NO (2-h incubation) was performed using labeled primers carrying the CCAAT-BF site or its mutated version (DeltaCCAAT-BF). For competition experiments, a 100x excess of unlabeled doubled-stranded oligonucleotide (cold probe) was added to the binding reaction. The results are expressed as the means +/- S.E. (n >/= 3). *, p < 0.05.
###end p 55
###begin p 56
###xml 168 169 167 168 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 330 336 329 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 478 482 477 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
Finally, we confirmed the importance of NO in inhibiting sGC promoter activity via the CCAAT-BF site, by EMSA. In accord with the luciferase assay data, DETA-NO (100 mum) caused an increase in the intensity of the three CCAAT-BF complexes observed that was essentially absent when using probes with a dysfunctional CCAAT-BF site (Fig. 7). However, despite attempting to produce a supershift in the CCAAT-BF complexes observed with specific antibodies to two putative CCAAT-BFs (e.g. CBF-B, MAZ), we were unable to observe such a change (data not shown), suggesting that additional CCAAT-BFs are likely involved.
###end p 56
###begin title 57
DISCUSSION
###end title 57
###begin p 58
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 153 154 153 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 557 561 557 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 1119 1120 1115 1116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1129 1130 1122 1123 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1108 1113 <span type="species:ncbi:9606">human</span>
###xml 1155 1160 <span type="species:ncbi:9606">human</span>
Activation of sGC is essential for NO-mediated regulation of vascular smooth muscle reactivity (5) and proliferation (6), microvascular permeability (7, 8), and the reactivity/adherence of platelets (9) and leukocytes (8, 11). As such, under physiological circumstances activation of sGC is fundamental to cardiovascular homeostasis and maintains an important cytoprotective/anti-thrombotic influence. Moreover, because inappropriate sGC activity may be responsible for several features of cardiovascular pathologies including blood pressure dysregulation (i.e. smooth muscle reactivity), capillary edema, and cellular recruitment, dysfunction of sGC is likely to have at least an equivalent impact on (patho)physiology as inappropriate NO production; changes in the expressional regulation (and activity) of this enzyme are therefore likely to exert considerable influence on the progression of disease. Despite this obvious importance, there exists scant information concerning the physiological regulation and pathological alterations of sGC expression. To address this deficit, we have characterized the human alpha1 and beta1 sGC promoter regions in human aortic smooth muscle cells.
###end p 58
###begin p 59
###xml 27 28 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 37 38 30 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 274 275 263 264 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 297 298 283 284 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 455 457 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref43">43</xref>
###xml 624 626 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref37">37</xref>
###xml 686 687 656 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 695 696 662 663 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 737 738 700 701 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 925 927 888 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref44">44</xref>
###xml 1011 1012 971 972 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 16 21 <span type="species:ncbi:9606">human</span>
###xml 534 539 <span type="species:ncbi:9606">human</span>
###xml 1001 1006 <span type="species:ncbi:9606">human</span>
Analysis of the human alpha1 and beta1 sGC gene promoters revealed some intriguing aspects of transcriptional regulation of these genes and differences in the promoter consensus core elements. Both sGC genes have a TATA-less promoter and show CCAAT-BF sites in direct (alpha1 sGC) or reverse (beta1 sGC) orientation approximately80 bp upstream from the putative transcription start site, in agreement with the canonical position for eukaryotic promoters (43). Classically, the following three-way combinations are highly favorable in human promoter regions to facilitate gene transcription: BRE-Inr-MTE and/or TATA-Inr-MTE (37); yet, neither combination was detected in either the alpha1 or beta1 sGC promoter. However, because the alpha1 sGC promoter exhibits two potential initiation modules, an alternative transcription start site 51 bp downstream given by the Inr-DPE module (and characteristic of TATA-less promoters) (44) cannot be ruled out. Surprisingly, an Inr element is not present in the human beta1 sGC promoter.
###end p 59
###begin p 60
###xml 82 83 78 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 92 93 85 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 221 222 210 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 385 386 371 372 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 726 728 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 835 836 818 819 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1122 1124 1105 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
Functional analysis of constructs containing different size fragments of the alpha1 and beta1 sGC 5'-flanking regions showed a slightly different profile of activity between both subunit promoters in HASMCs. Despite alpha1 sGC showing the highest promoter activity in the A0.3-kb construct, suggesting repressor elements localized further upstream, the situation was different for beta1 sGC. Here, the B0.5-kb construct showed the highest promoter activity, and the presence of several enhancers and repressors functioning at a distance from this regulatory region was detected. The fact that B0.5-kb activity was comparable with B0.8kb activity in HASMCs but has been shown to be over 3-fold lower than B0.8 kb in BE2 cells (34), suggests a cell-specific regulation of the crucial promoter region necessary to achieve the maximum beta1 sGC promoter activity in HASMCs. This cell-specific effect is also highlighted by the fact that B0.4-kb activity is almost the same as B0.5 kb and 2-fold higher than B0.3 kb in HASMCs, intimating strong activator elements located in the -253 to -354 region, not observed in BE2 cells (34). Thus, A0.3-kb and B0.5-kb constructs demonstrated the highest promoter activity in HASMCs, indicating that the regulatory promoter of sGC has all the necessary elements for maximum promoter activity in the 300-500-bp region upstream of the transcription start site.
###end p 60
###begin p 61
###xml 110 111 106 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 120 121 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 270 271 259 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 294 295 280 281 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 791 792 773 774 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 801 802 780 781 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 869 870 844 845 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 879 880 851 852 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 900 901 868 869 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1106 1107 1070 1071 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1116 1117 1077 1078 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1291 1293 1252 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
We also focused on the identification of principal TFs responsible for the transcriptional regulation of alpha1 and beta1 sGC in HASMCs. A multiplicity of putative transcription factor-binding sites predicted by MatInspector software are clustered in both A0.3-kb (alpha1 sGC) and B0.5-kb (beta1 sGC) promoter fragments, all of which have been shown to play an important role in the transcription of a wide variety of eukaryotic genes. GATA (GATA-binding factor, typical of the cardiovascular system), GFI1 (growth factor independence I; typical of the hematopoietic system), NFY (ubiquitous), and PBX (homeodomain factor; typical of the hematopoietic system) have consensus sequences in both promoters, and some of these factors may have a regulatory role in the co-expression of both alpha1 and beta1 sGC genes; this is particularly pertinent for the GFI1 (both alpha1 and beta1 sGC) and PBX (alpha1 sGC) sites, which are positioned between the CCAAT-BF site and the transcription start site and therefore are likely to play key roles in expressional regulation of sGC in hematopoiesis. Indeed, the alpha1 and beta1 sGC promoter regions contain no less than 20 consensus sequences for TFs reported to play a role in regulating hematopoiesis, supporting a key role for sGC in this process (34).
###end p 61
###begin p 62
###xml 43 44 39 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 524 525 520 521 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 586 588 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref45">45</xref>
###xml 697 699 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref46">46</xref>
###xml 984 985 976 977 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1042 1043 1030 1031 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Functional analysis with a luciferase alpha1 sGC reporter construct containing a c-Myb, GAGA, NFAT, or CCAAT-BF core deletion in the A0.3-kb promoter fragment demonstrated that the integrity of these sites is very important for transcription repression in HASMCs. The c-Myb and to a lesser extent the GAGA and NFAT repressor effects were not observed in COS-7 cells, intimating a vascular smooth muscle cell-specific effect. In fact, c-Myb plays a crucial role in arterial smooth muscle cell proliferation (associated with G1/S cell cycle transition), as occurs in many vasculopathies (45) and NFAT is associated with cardiac morphogenesis, vasculogenesis, and vascular smooth muscle hypertrophy (46); the physiological importance of NO-sGC signaling in curbing these proliferative processes fits with the ability of such TFs to suppress sGC promoter activity and thereby promote pathogenesis. However, it is noteworthy that when two other NFAT sites located at -174 and -161 in alpha1 sGC were mutated, they did not significantly alter alpha1 sGC promoter activity.
###end p 62
###begin p 63
###xml 42 43 39 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 293 295 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
Functional analysis with a luciferase beta1 sGC reporter construct containing a NFY core deletion in the B0.5-kb promoter fragment revealed that this site is critical for transcription activation in HASMCs, although this effect was less evident than in COS-7 cells (this study) and BE2 cells (34). Similar analysis also showed that the integrity of an NF-kappaB(p50) site is very important for transcription repression control, in both HASMCs and COS-7 cells, suggesting that this TF is globally important in constitutive gene expression.
###end p 63
###begin p 64
###xml 277 278 265 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 287 288 272 273 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 507 509 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref47">47</xref>
###xml 619 621 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref48">48</xref>
###xml 622 624 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref50">50</xref>
###xml 675 681 660 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 683 685 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 792 793 774 775 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 953 954 932 933 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1006 1008 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
To corroborate the importance of these TFs in regulation of sGC promoter activity, we conducted EMSAs to confirm the interaction of CCAAT-BF and NF-kappaB with the sGC promoter region. It is clear from these data that both CCAAT-BF and NF-kappaB(p50) bind strongly to the alpha1 and beta1 sGC promoter constructs, respectively, and that the effects of these TFs on sGC promoter activity are specific. A CCAAT-BF site has been found to be prevalent in the promoters of cell cycle-regulated eukaryotic genes (47) and is known to be essential for cell cycle-dependent activation and repression of several mammalian genes (48-50). In addition to the NFY site reported by Sharina et al. (34), a second upstream site was also shown to have an important role, highlighting the role NFY plays in beta1 sGC transcription. Moreover, the presence of the two closely situated NFY sites in the immediate promoter is in agreement with the idea that expression of beta1 sGC gene could be regulated during the cell cycle (34).
###end p 64
###begin p 65
###xml 788 789 784 785 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 798 799 791 792 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 869 870 858 859 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 878 879 864 865 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1041 1042 1019 1020 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1051 1052 1026 1027 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1296 1297 1268 1269 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Many cardiovascular diseases, particularly atherosclerosis, are now recognized to constitute a chronic inflammation of the blood vessel wall. Because NO-sGC-cGMP signaling exerts an important vasoprotective, anti-atherogenic effect, elucidation of the expressional regulation of sGC in a pro-inflammatory environment is likely to provide further insight into the pathogenesis of vascular disease. To mimic such a pathological scenario in the vasculature, we examined the effect of pro-inflammatory conditions on sGC promoter activity in HASMCs. A0.3-kb and B0.5-kb fragments were analyzed in the presence of a pro-inflammatory mixture. Under such conditions, sGC A0.3-kb and B0.5-kb promoter activity at 24 h was significantly reduced, demonstrating a coordinated regulation of both alpha1 and beta1 sGC gene expression. The fact that the strongest repressors for alpha1 ad beta1 sGC (CCAAT-BF and NF-kappaB, respectively) exhibit enhanced DNA binding under pro-inflammatory conditions might explain, at least in part, the reduction in alpha1 and beta1 sGC promoter activity observed under this "pathogenic" environment. Moreover, analysis of protein expression confirmed that the decreased promoter activity in the presence of pro-inflammatory mixture was mirrored by reductions in both sGC beta1 protein expression and activity, providing a key link between NF-kappaB and regulation of sGC bioactivity.
###end p 65
###begin p 66
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se</italic>
###xml 217 218 213 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 227 228 220 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 314 315 306 307 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 391 392 371 372 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 394 396 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref42">42</xref>
###xml 694 696 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref51">51</xref>
###xml 714 716 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref52">52</xref>
###xml 843 844 811 812 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
We also examined the effect of NO per se to mediate a feedback loop and prevent sGC promoter activity/expression. Using the NO donor DETA-NO, we demonstrated that NO exerts a concentration-dependent reduction in alpha1 and beta1 sGC promoter activity. In these studies, the inhibitory effect of NO peaked at 200 mum DETA-NO, which results in an ambient NO concentration of approximately200 nm (42), more akin to those associated with inducible NO synthase activity and pathological conditions (rather than generated by constitutive NO synthase). Moreover, the effects of NO in this respect appear to be cGMP-independent, implying direct effects on TF activity (as has been shown for NF-kappaB (51) and HIF-1alpha (52)). These studies also revealed that a CCAAT-BF site is pivotal to the inhibitory effects of NO, at least in terms of the alpha1 subunit, because deletion of this site leads to insensitivity to NO. Because several TFs bind this site, it is difficult to pinpoint which might be responsible; despite attempts to use EMSA-based supershifts to derive information concerning the identity of this TF, we were unable to elucidate the mechanism further (although we did obtain negative results for CBF-B and MAZ, suggesting that it is not either of these factors).
###end p 66
###begin p 67
###xml 578 580 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 616 618 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref53">53</xref>
###xml 636 638 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref54">54</xref>
###xml 640 642 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref55">55</xref>
The inflammation- and NO-based reduction in sGC promoter activity and protein expression might be likely to represent a common negative feedback regulation of sGC expression in cardiovascular disorders associated with high output NO production, such as septic shock. Here, it would be appropriate for sGC expression to be down-regulated to offset the excessive NO levels and thereby reverse the associated, life-threatening hypotension. These data also suggest that the reduction in sGC mRNA levels reported in vascular smooth muscle cells in response to LPS/interleukin-1beta (27), tumor necrosis factor-alpha/LPS (53), and NO donors (54, 55) is likely to be due, at least in part, to a direct down-regulation in sGC promoter activity via NF-kappaB(p50)- and CCAAT-BF-dependent pathways.
###end p 67
###begin p 68
###xml 342 343 338 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 352 353 345 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 165 170 <span type="species:ncbi:9606">human</span>
###xml 327 332 <span type="species:ncbi:9606">human</span>
In sum, these data provide a systematic, comparative analysis of human sGC promoter regulation in HASMCs and has identified potentially important factors regulating human sGC expression within a cell system relevant to cardiovascular physiology and (patho)physiology. These observations suggest that expressional regulation of human sGC alpha1 and beta1 subunit expression, both coordinated and individually, is likely to play an important role in the (patho)physiological regulation of enzyme activity. As such, these findings represent a significant advance in the understanding of expressional regulation of the genes encoding sGC subunits and provide insight into potential pathogenic mechanisms that result in aberrant NO-sGC signaling.
###end p 68
###begin title 69
Supplementary Material
###end title 69
###begin title 70
[Supplemental Data]
###end title 70
###begin p 71
###xml 117 122 <span type="species:ncbi:9606">human</span>
The abbreviations used are: sGC, soluble guanylyl cyclase; TF, transcription factor; LPS, lipopolysaccharide; HASMC, human aortic smooth muscle cell; DETA-NO, DETA-NONOate; EMSA, electrophoretic mobility shift assay; NFY, nuclear factor Y; A, alpha fragment; B, beta fragment.
###end p 71

